Many synthetic cannabinoids were designed by Stargate International, a now defunct New Zealand company in the 2000s and 2010s, and feature an alphanumeric code beginning with the prefix "SGT". PB-22 (SGT-21) is credited with being the first synthetic cannabinoid to feature a quinoline substructure with an ester linker at the indole 3-position. The mainly N-cumyl-indazole-3-carboxamide derivatives are best known. Many SGT compounds are banned as designer drugs in various jurisdictions, such as Japan.